Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | Not yet disclosed by govt.Likely | 24 | - |
| 2 | Schedule 2 | Not yet disclosed by govt.Likely | 24 | - |
| 3 | Schedule 3 | K R HOSPITAL CARELikely | 1 | ₹29,925 |
| 4 | Schedule 4 | Not yet disclosed by govt.Likely | 24 | - |
| 5 | Schedule 5 | K R HOSPITAL CARELikely | 1 | ₹1.1 L |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
4 Feb 2025, 10:00 amClosed
Inj Degludec insulin 100 IU per ml 3 ml pen Tresiba
Inj Glargine 100 IU per ml 3 ml pen
Inj Glulisine 100 IU per ml cart ADIPRA
Isabgoal husk 3 point 5 gm sachet
Human insulin analogue rapid acting inj 100 IU per ml Recombinant DNA origin 300 IU disposable pen with 5 needles per pen
Biphasic Isophane insulin 50 Human insulin 50 percent plus 50 percent isophane insulin suspension 100 IU per ml Mixtard 50
Insulin Glargine 450 IU per 1 point 5 ml pen
Amoxycillin 500 mg plus Clavulanic acid 125 mg tab Augmentin 625 mg
Tab Macvestin 500 mg Univestin
Volini gel tube of 30 gm Linseed oil plus Diclofenac plus Methyl Salicylate plus Menthol
Tab Canagliflozin 100 mg
Tab Semaglutide 3 mg
Tab Semaglutide 14 mg
Colostomy bag with flange 60 mm
Urostomy bag with flange 60 mm
7248306
GEM/2024/B/5706296
Two Packet Bid
Inj Degludec insulin 100 IU per ml 3 ml pen Tresiba
21 days
Gujarat; Vadodara
Item wise evaluation
BOQ
7 documents required · 7 mandatory
3 yrs
₹3
80%
Exempted
4 Feb 2025
14 Jan 2025
4 Feb 2025
| Item No | Item Title | Description | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|---|
| 1 | Inj Degludec insulin 100 IU per ml 3 ml pen Tresiba | Inj Degludec insulin 100 IU per ml pen Tresiba | 150 | Pen | VADODARA CITY | 21 |
| 2 | Inj Glargine 100 IU per ml 3 ml pen | Inj Glargine 100 IU per ml 3 ml pen | 276 | Pen | VADODARA CITY | 21 |
| 3 | Inj Glulisine 100 IU per ml cart ADIPRA | Inj Glulisine 100 IU per ml cart ADIPRA | 75 | Cart | VADODARA CITY | 21 |
| 4 | Isabgoal husk 3 point 5 gm sachet | Isabgoal husk 3 point 5 gm sachet | 3,900 | Sachet | VADODARA CITY | 21 |
| 5 | Human insulin analogue rapid acting inj 100 IU per ml Recombinant DNA origin 300 IU disposable pen with 5 needles per pen | Human insulin analogue rapid acting inj 100 IU per ml Recombinant DNA origin 300 IU disposable pen with 5 needles per pen | 180 | Pen | VADODARA CITY | 21 |
| 6 | Biphasic Isophane insulin 50 Human insulin 50 percent plus 50 percent isophane insulin suspension 100 IU per ml Mixtard 50 | Biphasic Isophane insulin 50 Human insulin 50 percent plus 50 percent isophane insulin suspension 100 IU per ml Mixtard 50 | 50 | Pen | VADODARA CITY | 21 |
| 7 | Insulin Glargine 450 IU per 1 point 5 ml pen | Insulin Glargine 450 IU per 1 point 5 ml pen | 120 | Pen | VADODARA CITY | 21 |
| 8 | Amoxycillin 500 mg plus Clavulanic acid 125 mg tab Augmentin 625 mg | Amoxycillin 500 mg plus Clavulanic acid 125 mg tab Augmentin 625 mg | 4,200 | No | VADODARA CITY | 21 |
| 9 | Tab Macvestin 500 mg Univestin | Tab Macvestin 500 mg Univestin | 3,000 | No | VADODARA CITY | 21 |
| 10 | Volini gel tube of 30 gm Linseed oil plus Diclofenac plus Methyl Salicylate plus Menthol | Volini gel tube of 30 gm Linseed oil plus Diclofenac plus Methyl Salicylate plus Menthol | 1,500 | Tube | VADODARA CITY | 21 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_7248306.pdf
GEM_BID
docscanner_13-dec-2024_11-10_pm_2024-12-13-23-54-32_163f7c5705d70072f3d44255254241c9.pdf
BOQ
boq_item_sample_file-2_2024-12-13-23-54-32_3e6f2b31590161c59ccf0805c17132cd.csv
BOQ
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .